Pimecrolimus in dermatology: atopic dermatitis and beyond.

  title={Pimecrolimus in dermatology: atopic dermatitis and beyond.},
  author={Paolo Gisondi and Charles N. Ellis and Giampiero Girolomoni},
  journal={International journal of clinical practice},
  volume={59 8},
Pimecrolimus is a calcineurin inhibitor developed for the topical therapy of inflammatory skin diseases, particularly atopic dermatitis (AD). Pimecrolimus selectively targets T cells and mast cells. Pimecrolimus inhibits T-cell proliferation, as well as production and release of interleukin-2 (IL-2), IL-4, interferon-gamma and tumour necrosis factor-alpha. Moreover, pimecrolimus inhibits mast cell degranulation. In contrast to tacrolimus, pimecrolimus has no effects on the differentiation… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 16 extracted citations


Publications referenced by this paper.
Showing 1-10 of 37 references

Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study

  • KA Papp, T Werfel, R Folster-Holst
  • J Am Acad Dermatol
  • 2005

Similar Papers

Loading similar papers…